<?xml version='1.0' encoding='utf-8'?>
<document id="30377854"><sentence text="Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir."><entity charOffset="131-140" id="DDI-PubMed.30377854.s1.e0" text="Odalasvir" /><entity charOffset="148-158" id="DDI-PubMed.30377854.s1.e1" text="Simeprevir" /><pair ddi="false" e1="DDI-PubMed.30377854.s1.e0" e2="DDI-PubMed.30377854.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30377854.s1.e0" e2="DDI-PubMed.30377854.s1.e1" /></sentence><sentence text="The aim of the current study was to characterize the time course of plasma concentrations of AL-335 and its main metabolites (ALS-022399 and ALS-022227) after oral administration in healthy and hepatitis C virus (HCV)-infected subjects, in monotherapy as well as in combination with simeprevir and/or odalasvir"><entity charOffset="283-293" id="DDI-PubMed.30377854.s2.e0" text="simeprevir" /></sentence><sentence text=" AL-335, ALS-022399, and ALS-022227 plasma concentrations from subjects receiving 800 mg of AL-335 orally once daily (qd) as monotherapy or in combination were pooled and analyzed using a nonlinear mixed effect modeling approach" /><sentence text=" The typical values (between subject variability) of AL-335 and ALS-022399 apparent linear clearances were 3300 L/h (33" /><sentence text="9%) and 1910 L/h (30" /><sentence text="0%), respectively" /><sentence text=" ALS-022227 elimination was characterized as a nonlinear process, with typical values of Vmax,ALS-022227 and Km,ALS-022227 estimated to be 84,799 ng/h (14" /><sentence text="9%) and 450" /><sentence text="2 ng/mL, respectively" /><sentence text=" AL-335 and ALS-022399 plasma concentrations were increased more than 2-fold in presence of simeprevir and/or odalasvir, while the effect on ALS-022227 plasma concentrations was limited"><entity charOffset="92-102" id="DDI-PubMed.30377854.s10.e0" text="simeprevir" /><entity charOffset="110-119" id="DDI-PubMed.30377854.s10.e1" text="odalasvir" /><pair ddi="false" e1="DDI-PubMed.30377854.s10.e0" e2="DDI-PubMed.30377854.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30377854.s10.e0" e2="DDI-PubMed.30377854.s10.e1" /></sentence><sentence text=" The effect of simeprevir and/or odalasvir might be explained by their capacity to inhibit P-glycoprotein"><entity charOffset="15-25" id="DDI-PubMed.30377854.s11.e0" text="simeprevir" /><entity charOffset="33-42" id="DDI-PubMed.30377854.s11.e1" text="odalasvir" /><pair ddi="false" e1="DDI-PubMed.30377854.s11.e0" e2="DDI-PubMed.30377854.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30377854.s11.e0" e2="DDI-PubMed.30377854.s11.e1" /></sentence><sentence text=" Internal evaluation confirmed that the population pharmacokinetic model developed was deemed appropriate to describe the time course of AL-335, ALS-022399, and ALS-022227 plasma concentrations and their associated variability in both healthy and HCV-infected subjects, as well as the interaction effect of simeprevir and/or odalasvir over AL-335 and its metabolites in healthy subjects"><entity charOffset="307-317" id="DDI-PubMed.30377854.s12.e0" text="simeprevir" /></sentence><sentence text=" This model can be used as a starting point to evaluate drug-drug interaction processes in HCV-infected patients and support the development of a direct-acting antiviral (DAA) combination" /><sentence text="" /></document>